EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation

Tilman Schneider-Hohendorf iD, Christian Wünsch, Simon Falk, Catarina Raposo, Florian Rubelt, Hamid Mirebrahim, Hosseinali Asgharian, Ulrich Schlecht, Daniel Mattox, Wenyu Zhou, Eva Dawin, Marc Pawlitzki und 25 weitere

Brain · 2025

DOI: 10.1093/brain/awae244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Tilman Schneider-Hohendorf und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology with Institute of Translational Neurology, University of Muenster, 48149 Muenster, Germany. Hauptthemen laut MEDLINE: Multiple Sclerosis, Herpesvirus 4, Human, Epstein-Barr Virus Infections, Receptors, Antigen, T-Cell, alpha-beta. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, H.W., C.C.G. and H.W..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epstein-Barr virus (EBV) infection has long been associated with the development of multiple sclerosis (MS). Patients with MS have elevated titres of EBV-specific antibodies in serum and show signs of CNS damage only after EBV infection. Regarding CD8+ T cells, an elevated but ineffective response to EBV was suggested in MS patients, who present with a broader MHC-I-restricted EBV-specific T-cell receptor beta chain (TRB) repertoire compared to controls. It is not known whether this altered EBV response could be subject to dynamic changes, e.g. by approved MS therapies, and whether it is specific for MS. Peripheral blood TRB repertoire samples (n = 1317) of healthy donors (n = 409), patients with MS (n = 710) before and after treatment, patients with neuromyelitis optica spectrum disorder (n = 87), MOG antibody-associated disease (MOGAD) (n = 64) and Susac’s syndrome (n = 47) were analysed. Apart from MS, none of the evaluated diseases presented with a broader anti-EBV TRB repertoire. In MS patients undergoing autologous haematopoietic stem-cell transplantation, EBV reactivation coincided with elevated MHC-I-restricted EBV-specific TRB sequence matches. Therapy with ocrelizumab, teriflunomide or dimethyl fumarate reduced EBV-specific, but not CMV-specific MHC-I-restricted TRB sequence matches. Together, these data suggest that the aberrant MHC-I-restricted T-cell response directed against EBV is specific to MS with regard to neuromyelitis optica, MOGAD and Susac’s syndrome and that it is specifically modified by MS treatments interfering with EBV host cells or activated lymphocytes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisHerpesvirus 4, HumanEpstein-Barr Virus InfectionsReceptors, Antigen, T-Cell, alpha-betaHumansFemaleMaleAdultMiddle AgedAntibodies, Monoclonal, HumanizedYoung AdultNeuromyelitis Optica

Stichwörter der Autor:innen

Epstein-Barr virusSusac’s syndromeT-cell receptormultiple sclerosismyelin-oligodendrocyte-glycoprotein antibody-associated diseaseneuromyelitis optica spectrum disorder

Substanzen

Receptors, Antigen, T-Cell, alpha-betaAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Neurology with Institute of Translational Neurology, University of Muenster, 48149 Muenster, Germany.
  • F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.
  • Roche Sequencing Solutions, 4300 Pleasanton, CA, USA.
  • Adaptive Biotechnologies, 98109 Seattle, WA, USA.
  • Department of Neurology, Otto von Guericke University, 39106 Magdeburg, Germany.
  • Department of Neurology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, Germany.

ORCID-Profile: Tilman Schneider-Hohendorf, Tania Kümpfel, Nicholas Schwab

Förderung

  • Deutsche Forschungsgemeinschaft
  • H.W.
  • C.C.G. and H.W.

Zitieren

APA

Schneider-Hohendorf, T., Wünsch, C., Falk, S., Raposo, C., Rubelt, F., Mirebrahim, H., Asgharian, H., Schlecht, U., Mattox, D., Zhou, W., Dawin, E., Pawlitzki, M., Lauks, S., Jarius, S., Wildemann, B., Havla, J., Kümpfel, T., Schrot, M. C., Ringelstein, M., …, & Schwab, N. (2025). Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation. Brain. https://doi.org/10.1093/brain/awae244

Vancouver

Schneider-Hohendorf T, Wünsch C, Falk S, Raposo C, Rubelt F, Mirebrahim H, et al. Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation. Brain. 2025. doi:10.1093/brain/awae244

BibTeX
@article{SchneiderHohendorf2025,
  author = {Schneider-Hohendorf, Tilman and Wünsch, Christian and Falk, Simon and Raposo, Catarina and Rubelt, Florian and Mirebrahim, Hamid and Asgharian, Hosseinali and Schlecht, Ulrich and Mattox, Daniel and Zhou, Wenyu and Dawin, Eva and Pawlitzki, Marc and Lauks, Sarah and Jarius, Sven and Wildemann, Brigitte and Havla, Joachim and Kümpfel, Tania and Schrot, Miriam-Carolina and Ringelstein, Marius and Kraemer, Markus and Schwake, Carolin and Schmitter, Thomas and Ayzenberg, Ilya and Fischer, Katinka and Meuth, Sven G and Aktas, Orhan and Hümmert, Martin W and Kretschmer, Julian R and Trebst, Corinna and Kleffner, Ilka and Massey, Jennifer and Muraro, Paolo A and Chen-Harris, Haiyin and Gross, Catharina C and Klotz, Luisa and Wiendl, Heinz and Schwab, Nicholas},
  title = {Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation},
  journal = {Brain},
  year = {2025},
  doi = {10.1093/brain/awae244}
}
Kostenlos starten →